Intellia Therapeutics, Inc.
NTLA
$11.91
$0.080.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -399.98M | -394.60M | -412.69M | -445.81M | -480.19M |
| Total Depreciation and Amortization | 15.24M | 15.63M | 15.92M | 12.47M | 10.15M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.21M | 67.95M | 75.79M | 94.89M | 118.14M |
| Change in Net Operating Assets | -28.11M | -52.13M | -73.75M | -72.21M | -66.67M |
| Cash from Operations | -346.64M | -363.15M | -394.74M | -410.65M | -418.58M |
| Capital Expenditure | -2.04M | -473.00K | -1.13M | -1.98M | -3.23M |
| Sale of Property, Plant, and Equipment | 90.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -46.52M | 200.49M | 229.16M | 354.05M | 348.33M |
| Cash from Investing | -48.47M | 200.01M | 228.03M | 352.06M | 345.09M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 346.52M | 165.06M | 131.49M | 131.83M | 99.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 346.52M | 165.06M | 131.49M | 131.83M | 99.16M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.59M | 1.92M | -35.22M | 73.24M | 25.67M |